Manager × security

Persistent Asset Partners Ltd BMRN holdings history

Who else holds this security? →

BIOMARIN PHARMACEUTICAL INC · CUSIP 09061G101 · CIK 2056052

Citable facts

As of 2026-06-30, Persistent Asset Partners Ltd reported 79.93K BMRN (shares), valued at $4.57M, or 1.44% of its reported non-derivative portfolio. Filed 2026-08-07.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
1.44%
Shares
79.93K
79,933
Reported value
$4.57M
USD

Shares increased 113.31%; reported value increased 116.07%, and weight changed +0.62 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20261.44%79,933SEC filing ↗Filed Aug 7, 2026
Q1 20260.82%37,472SEC filing ↗Filed May 12, 2026
Q4 20251.12%39,135SEC filing ↗Filed Feb 17, 2026
Q3 20251.92%48,866SEC filing ↗Filed Nov 10, 2025Amended
Q2 20252.13%44,264SEC filing ↗Filed Aug 11, 2025
Q1 20250.75%12,083SEC filing ↗Filed May 13, 2025
Q4 20241.46%26,856SEC filing ↗Filed Feb 14, 2025
Q3 2024Not reportedNot reportedNo filing this quarter
Q2 2024Not reportedNot reportedNo filing this quarter
Q1 2024Not reportedNot reportedNo filing this quarter
Q4 2023Not reportedNot reportedNo filing this quarter
Q3 2023Not reportedNot reportedNo filing this quarter

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 2023Not reported——The manager filed nothing for this quarter; a missing quarter is not treated as zero holdings.—
Q4 2023Not reported——The manager filed nothing for this quarter; a missing quarter is not treated as zero holdings.—
Q1 2024Not reported——The manager filed nothing for this quarter; a missing quarter is not treated as zero holdings.—
Q2 2024Not reported——The manager filed nothing for this quarter; a missing quarter is not treated as zero holdings.—
Q3 2024Not reported——The manager filed nothing for this quarter; a missing quarter is not treated as zero holdings.—
Q4 20241.46%26,856$1.70MA comparable prior-quarter record is unavailable; changes are not inferred.SEC filing ↗
Filed Feb 14, 2025
Q1 20250.75%12,083$854.15KShares decreased 55.01%; reported value decreased 49.80%, and weight changed -0.71 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 13, 2025
Q2 20252.13%44,264$2.43MShares increased 266.33%; reported value increased 184.87%, and weight changed +1.38 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 11, 2025
Q3 20251.92%48,866$2.65MShares increased 10.40%; reported value increased 8.77%, and weight changed -0.21 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 10, 2025
Q4 20251.12%39,135$2.33MShares decreased 19.91%; reported value decreased 12.12%, and weight changed -0.80 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 17, 2026
Q1 20260.82%37,472$2.12MShares decreased 4.25%; reported value decreased 8.99%, and weight changed -0.30 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 12, 2026
Q2 20261.44%79,933$4.57MShares increased 113.31%; reported value increased 116.07%, and weight changed +0.62 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 7, 2026
Persistent Asset Partners Ltd · BIOMARIN PHARMACEUTICAL INC

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"2056052","quarter":"2026Q2","cusip":"09061G101"}

get_institutional_manager_history
{"cik":"2056052","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.